NCT02807987

Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

A Study of CS-3150 to Evaluate Efficacy and Safety in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Daiichi Sankyo Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.

Conditions

• Hypertension With Moderate Renal Impairment

Interventions

Type	Name	Description
DRUG	CS-3150	CS-3150 1.25 to 2.5, 5mg, orally

Timeline

• Start date: 2016-06-01
• Primary completion: 2017-05-15
• Completion: 2017-05-15
• First posted: 2016-06-21
• Last updated: 2018-12-21

Locations

1 site across 1 country: Japan